DOXIMITY INC-CLASS A (DOCS) Stock Fundamental Analysis
NYSE:DOCS - New York Stock Exchange, Inc. - US26622P1075 - Common Stock - Currency: USD
DOCS gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 36 industry peers in the Health Care Technology industry. DOCS gets an excellent profitability rating and is at the same time showing great financial health properties. DOCS is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! This makes DOCS very considerable for growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year DOCS was profitable.
In the past year DOCS had a positive cash flow from operations.
DOCS had positive earnings in each of the past 5 years.
DOCS had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 17.65%, DOCS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
DOCS has a Return On Equity of 20.62%. This is amongst the best in the industry. DOCS outperforms 100.00% of its industry peers.
Looking at the Return On Invested Capital, with a value of 17.07%, DOCS belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for DOCS is significantly above the industry average of 6.38%.
The last Return On Invested Capital (17.07%) for DOCS is above the 3 year average (14.17%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.65% | ||
| ROE | 20.62% | ||
| ROIC | 17.07% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
1.3 Margins
DOCS has a Profit Margin of 39.13%. This is amongst the best in the industry. DOCS outperforms 100.00% of its industry peers.
DOCS's Profit Margin has improved in the last couple of years.
DOCS has a better Operating Margin (40.34%) than 100.00% of its industry peers.
DOCS's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 90.20%, DOCS belongs to the top of the industry, outperforming 97.22% of the companies in the same industry.
DOCS's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 40.34% | ||
| PM (TTM) | 39.13% | ||
| GM | 90.2% |
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), DOCS is creating some value.
The number of shares outstanding for DOCS has been increased compared to 1 year ago.
Compared to 5 years ago, DOCS has more shares outstanding
There is no outstanding debt for DOCS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 40.32 indicates that DOCS is not in any danger for bankruptcy at the moment.
DOCS's Altman-Z score of 40.32 is amongst the best of the industry. DOCS outperforms 97.22% of its industry peers.
DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 40.32 |
ROIC/WACC1.6
WACC10.64%
2.3 Liquidity
A Current Ratio of 6.97 indicates that DOCS has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 6.97, DOCS belongs to the top of the industry, outperforming 94.44% of the companies in the same industry.
A Quick Ratio of 6.97 indicates that DOCS has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 6.97, DOCS belongs to the best of the industry, outperforming 94.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.97 | ||
| Quick Ratio | 6.97 |
3. Growth
3.1 Past
DOCS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 48.42%, which is quite impressive.
The Earnings Per Share has been growing by 79.21% on average over the past years. This is a very strong growth
The Revenue has grown by 19.97% in the past year. This is quite good.
The Revenue has been growing by 37.42% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)48.42%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%52%
Revenue 1Y (TTM)19.97%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%17.14%
3.2 Future
Based on estimates for the next years, DOCS will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.53% on average per year.
Based on estimates for the next years, DOCS will show a quite strong growth in Revenue. The Revenue will grow by 10.57% on average per year.
EPS Next Y2.49%
EPS Next 2Y7.75%
EPS Next 3Y10.11%
EPS Next 5Y17.53%
Revenue Next Year10.68%
Revenue Next 2Y10.59%
Revenue Next 3Y10.54%
Revenue Next 5Y10.57%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 43.65 indicates a quite expensive valuation of DOCS.
Based on the Price/Earnings ratio, DOCS is valued a bit cheaper than 75.00% of the companies in the same industry.
When comparing the Price/Earnings ratio of DOCS to the average of the S&P500 Index (27.52), we can say DOCS is valued expensively.
A Price/Forward Earnings ratio of 42.59 indicates a quite expensive valuation of DOCS.
DOCS's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. DOCS is cheaper than 61.11% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.58, DOCS is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.65 | ||
| Fwd PE | 42.59 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of DOCS indicates a somewhat cheap valuation: DOCS is cheaper than 66.67% of the companies listed in the same industry.
DOCS's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. DOCS is cheaper than 66.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 43.34 | ||
| EV/EBITDA | 41.28 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of DOCS may justify a higher PE ratio.
PEG (NY)17.56
PEG (5Y)0.55
EPS Next 2Y7.75%
EPS Next 3Y10.11%
5. Dividend
5.1 Amount
DOCS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
61.55
+1.35 (+2.24%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners93.81%
Inst Owner Change-0.04%
Ins Owners2.25%
Ins Owner Change-2.03%
Market Cap11.56B
Analysts76.15
Price Target62.73 (1.92%)
Short Float %4.18%
Short Ratio2.16
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.65%
Min EPS beat(2)30.62%
Max EPS beat(2)36.67%
EPS beat(4)4
Avg EPS beat(4)26.68%
Min EPS beat(4)15.86%
Max EPS beat(4)36.67%
EPS beat(8)8
Avg EPS beat(8)24.85%
EPS beat(12)12
Avg EPS beat(12)22.9%
EPS beat(16)16
Avg EPS beat(16)34.8%
Revenue beat(2)2
Avg Revenue beat(2)4.77%
Min Revenue beat(2)1.38%
Max Revenue beat(2)8.16%
Revenue beat(4)4
Avg Revenue beat(4)4.65%
Min Revenue beat(4)1.38%
Max Revenue beat(4)8.16%
Revenue beat(8)6
Avg Revenue beat(8)2.85%
Revenue beat(12)8
Avg Revenue beat(12)1.88%
Revenue beat(16)12
Avg Revenue beat(16)3.35%
PT rev (1m)0.05%
PT rev (3m)-18.38%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.11%
EPS NY rev (1m)8.19%
EPS NY rev (3m)-0.02%
Revenue NQ rev (1m)-0.09%
Revenue NQ rev (3m)-2.59%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)-1.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.65 | ||
| Fwd PE | 42.59 | ||
| P/S | 20.27 | ||
| P/FCF | 43.34 | ||
| P/OCF | 42.31 | ||
| P/B | 10.68 | ||
| P/tB | 11.66 | ||
| EV/EBITDA | 41.28 |
EPS(TTM)1.41
EY2.29%
EPS(NY)1.45
Fwd EY2.35%
FCF(TTM)1.42
FCFY2.31%
OCF(TTM)1.45
OCFY2.36%
SpS3.04
BVpS5.76
TBVpS5.28
PEG (NY)17.56
PEG (5Y)0.55
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.65% | ||
| ROE | 20.62% | ||
| ROCE | 20.77% | ||
| ROIC | 17.07% | ||
| ROICexc | 98.29% | ||
| ROICexgc | 186.54% | ||
| OM | 40.34% | ||
| PM (TTM) | 39.13% | ||
| GM | 90.2% | ||
| FCFM | 46.76% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
ROICexc(3y)82.49%
ROICexc(5y)193.92%
ROICexgc(3y)186.25%
ROICexgc(5y)N/A
ROCE(3y)17.25%
ROCE(5y)20.05%
ROICexcg growth 3Y3.35%
ROICexcg growth 5YN/A
ROICexc growth 3Y-4.75%
ROICexc growth 5YN/A
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
F-Score9
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 61.22% | ||
| Cap/Sales | 1.14% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 113.5% | ||
| Profit Quality | 119.52% | ||
| Current Ratio | 6.97 | ||
| Quick Ratio | 6.97 | ||
| Altman-Z | 40.32 |
F-Score9
WACC10.64%
ROIC/WACC1.6
Cap/Depr(3y)59.31%
Cap/Depr(5y)83.25%
Cap/Sales(3y)1.28%
Cap/Sales(5y)1.55%
Profit Quality(3y)131.35%
Profit Quality(5y)169.54%
High Growth Momentum
Growth
EPS 1Y (TTM)48.42%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%52%
EPS Next Y2.49%
EPS Next 2Y7.75%
EPS Next 3Y10.11%
EPS Next 5Y17.53%
Revenue 1Y (TTM)19.97%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%17.14%
Revenue Next Year10.68%
Revenue Next 2Y10.59%
Revenue Next 3Y10.54%
Revenue Next 5Y10.57%
EBIT growth 1Y33.93%
EBIT growth 3Y26.56%
EBIT growth 5Y59.63%
EBIT Next Year12.42%
EBIT Next 3Y11.62%
EBIT Next 5Y11.91%
FCF growth 1Y49.61%
FCF growth 3Y30.18%
FCF growth 5Y64.72%
OCF growth 1Y48.44%
OCF growth 3Y29.24%
OCF growth 5Y59.83%